News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
financialcontent.com Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
ImmuCell Corporation (ICCC) is a biotechnology company focused on veterinary products, particularly for enhancing immune health in livestock. The company's stock recently traded at $10.20, down 6.47%, and has a market cap of $78.93 million. Recent news highlights include Q2 2026 earnings results, increased …
Key Points Interested in ImmuCell Corporation? Here are five stocks we like better. Strong domestic growth drove results: Second-quarter product sales rose 11.5% year over year to $7.2 million, while net income increased to $1.8 million from $500,000. Domestic sales grew 27.7%, offsetting a …
ImmuCell (NASDAQ:ICCC) reported its earnings results, beating the consensus estimate by $0.15 EPS with reported earnings of $0.20 per share. The biotechnology company also surpassed revenue expectations, bringing in $7.19 million against an anticipated $5.40 million. Despite these positive financial results, the company maintains …
IMMUCELL CORP /DE/ (ICCC) reported strong second-quarter 2026 results, with revenue reaching $7.19M and diluted EPS of $0.20, significantly up from the previous year. This growth was primarily driven by increased volumes and pricing for its First Defense product, which accounted for over 99% …
ImmuCell (NASDAQ: ICCC) reported strong Q2 2026 financial results with product sales up 11.5% to $7.2 million and net income rising to $1.8 million, aided by a $2 million legal settlement. The company announced a two-phase, approximately $8.0 million expansion of its First Defense® …
ImmuCell Corporation reported robust financial results for the first half of 2026, with net income doubling to $3.8 million due to increased First Defense sales and a significant $2.0 million settlement. The company's product sales grew by 20.9% to $17.5 million, largely driven by …
This article provides an earnings forecast for ImmuCell Corp (ICCC), including future estimates for EPS and revenue growth. It presents current stock performance data, market capitalization, and indicates that the financial forecasts were updated on August 8, 2026. The content also lists peer comparisons …
ImmuCell (Nasdaq: ICCC) will report its unaudited financial results for the quarter ended June 30, 2026, after market close on August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results, …
ImmuCell Corporation will announce its unaudited financial results for the quarter ended June 30, 2026, after market close on Thursday, August 13, 2026. The company will host a conference call and webcast on August 14, 2026, at 9:00 AM ET to discuss these results. …
ImmuCell Corp (ICCC) has a stable financial status with a current score of 8.98, ranking it 17th out of 155 in the Pharmaceuticals industry. The company demonstrated high operating efficiency with its latest quarterly revenue increasing by 28.39% year-over-year to $10.36M, and net profit …
This article provides a detailed quarterly and annual income statement for ImmuCell Corp (ICCC), covering various financial metrics from total revenue to diluted earnings per share. It offers insights into the company's financial performance and operational efficiency over several fiscal years and quarters. The …
This article provides a comprehensive stock analysis of ImmuCell Corp (ICCC) from TradingKey, highlighting its healthy fundamentals, high growth potential, and a 'fairly valued' assessment within the Pharmaceuticals industry. The analysis notes strong institutional ownership and anticipates an upward trend in the medium term, …
This article provides an overview of ImmuCell Corp's (ICCC) dividend history, noting that the company has not distributed any dividends over the past five years. It presents current stock price information and links to more detailed financial and corporate data. The page indicates that …
This article provides a revenue breakdown for ImmuCell Corp (ICCC), detailing its performance by business segments and regional contributions. The data, updated on April 6, shows that the First Defense® product line accounts for the vast majority of its revenue, and the United States …
This article provides an in-depth look at ImmuCell Corp's (ICCC) cash flow statements, including operating, investing, and financing activities, across various fiscal quarters and years. It also defines key cash flow metrics like operating, investing, and financing cash flow, as well as free cash …
This article provides a valuation analysis of ImmuCell Corp (ICCC), noting its current valuation score of 8.64, which ranks it 84th out of 155 in the Pharmaceuticals industry. The company's P/E ratio is reported as -178.77, though key data for P/B, P/S, and P/CF …
Search by ticker symbol or company name and select a result to open its chart.